<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="921">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01554683</url>
  </required_header>
  <id_info>
    <org_study_id>2011P000303</org_study_id>
    <nct_id>NCT01554683</nct_id>
  </id_info>
  <brief_title>Seizure Activity in Alzheimer's Disease</brief_title>
  <official_title>Seizure-like Hippocampal Activity in Alzheimer's Disease Neurodegeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this research project is to study how seizure-like activity affects the&#xD;
      blood flow in the brain of patients with Alzheimer's disease (AD). Changes in blood flow can&#xD;
      change memory and thinking ability, as happens in Alzheimer's disease. The investigators are&#xD;
      using a study drug called Levetiracetam, which helps control seizure-like activity to see if&#xD;
      it can help change the abnormal blood flow in the brain that is seen in some people with&#xD;
      Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will make four separate visits to BIDMC. Subject will come to the Clinical Research&#xD;
      Center. All of the visits will take around 5 hours apiece.&#xD;
&#xD;
      If subjects agree to be in this study, subjects will be asked to read and sign the consent&#xD;
      form. After subjects sign the consent form, the following things will happen:&#xD;
&#xD;
        1. Screening Procedures: Screening procedures are tests and procedures that will be done to&#xD;
           determine if subjects are eligible to take part in the research study. For this research&#xD;
           study, the screening procedures include:&#xD;
&#xD;
             -  A thorough medical history. Investigators will ask if subjects have any medical&#xD;
                problems. Investigators will ask about subjects Alzheimer's disease and if they&#xD;
                have had any seizures.&#xD;
&#xD;
             -  A physical examination. Investigators will take your blood pressure and your heart&#xD;
                rate. They will examine your heart and lungs and take your height and weight&#xD;
&#xD;
             -  Investigators will also assess the subject's nervous system. Investigators will&#xD;
                examine subject's speech, memory, strength, coordination, and reflexes.&#xD;
&#xD;
             -  Investigators will ask you to take some paper and pencil tests. This will help us&#xD;
                to understand your memory and mood&#xD;
&#xD;
             -  Subjects will have a blood test to check how your kidneys are functioning.&#xD;
&#xD;
           Subjects may have already had some of these tests done by their doctor when they were&#xD;
           diagnosed with Alzheimer's disease.&#xD;
&#xD;
           The information we learned will help to decide whether subjects could join the study.&#xD;
           Investigators will explain the reason if they decide subjects should not join the study.&#xD;
           Our decision does NOT mean that subjects have a health problem or disorder .&#xD;
&#xD;
        2. Randomization Procedures: Investigators will meet with one of the study doctors if&#xD;
           subjects continue in the study. The study doctor will explain to subjects when they are&#xD;
           expected to come to the research center for study testing or to take the study drug.&#xD;
           Subjects will come to the BIDMC Clinical Research Center for three visits. These visits&#xD;
           will occur within one month.&#xD;
&#xD;
           All study participants will receive the same study drugs over the three (3) visits.&#xD;
&#xD;
             -  Subjects will receive levetiracetam, the study drug, in a low dose, 2.5 milligrams&#xD;
                for each kilogram of body weight, at one visit.&#xD;
&#xD;
             -  Subjects will receive levetiracetam, the study drug, in a high dose, 7.5 milligrams&#xD;
                for each kilogram of body weight, at one visit.&#xD;
&#xD;
             -  Subjects will receive a placebo at one visit.&#xD;
&#xD;
           A placebo is an inactive injection that looks like the study drug, but a placebo&#xD;
           contains no active medication. In this study, the placebo is a saline (sterile salt&#xD;
           water) injection.&#xD;
&#xD;
           Sometimes study results are truly due to the study medication. Sometimes the study&#xD;
           results are not due to the study medication. Investigators are using a placebo to help&#xD;
           us understand the reason for the results in this study.&#xD;
&#xD;
           The order of the above visits will not be the same for all study participants. There are&#xD;
           six different orders to receive the study drugs. For example, subjects could receive the&#xD;
           placebo at the first visit, the high dose of levetiracetam at the second visit, and the&#xD;
           low dose of levetiracetam at the third visit. Another example is that subjects could&#xD;
           receive the low dose at the first visit, the placebo at the second visit, and the high&#xD;
           dose at the third visit.&#xD;
&#xD;
           Deciding the order in which you get the study drugs will be done by to a method called&#xD;
           &quot;randomization.&quot; Randomization means that a computer will assign patients to study drugs&#xD;
           in a random manner, like flipping a coin. Another way to say randomization is &quot;by&#xD;
           chance.&quot; When you flip a coin, you get heads or tails by chance. The chance of getting&#xD;
           any dose of study drug or placebo is about equal. After the randomization, Subjects will&#xD;
           be assigned to get one study drug or placebo at each visit. Subjects will not be able to&#xD;
           choose which study drug you will get at each visit.&#xD;
&#xD;
           Subjects will not know which study drug dose or placebo will be given at a visit. The&#xD;
           study doctor will not know which study drug dose or placebo will be given at a visit.&#xD;
           The study doctor can find out this information quickly if there is an emergency.&#xD;
&#xD;
        3. Research Procedures: Subjects will come to the BIDMC Clinical Research Center three&#xD;
           times if they continue in this study. A member of the study team will meet subjects when&#xD;
           they arrive. Subjects will first have an intravenous catheter (also called an IV) put&#xD;
           into a vein. A nurse will check blood pressure and heart rate. Subjects will have a&#xD;
           brief physical exam and a nervous system exam by a doctor&#xD;
&#xD;
           Subjects will then have an electroencephalogram (EEG). An EEG gives investigators&#xD;
           information about the nervous system - specifically the brain. Subjects will have their&#xD;
           scalp cleaned with alcohol and small discs - called electrodes - placed on the scalp&#xD;
           using gel. Then the head will be will be wrapped with gauze to. keep the discs from&#xD;
           moving. The discs will be attached by wires to an EEG machine. The EEG machine will be&#xD;
           at the bedside and will give investigators information about the electrical activity in&#xD;
           the brain. Subjects will need to lie quietly with eyes closed during the one hour that&#xD;
           the EEG machine is attached. Investigators will clean the gel from hair and skin when&#xD;
           the EEG is over.&#xD;
&#xD;
           Investigators will give subjects either levetiracetam -- the study drug -- or placebo&#xD;
           while subjects are having EEG. Investigators will give subjects the study drug or&#xD;
           placebo through the intravenous catheter (&quot;IV&quot;) in the arm. This will take around 20 to&#xD;
           30 minutes. The subjects nurse will take the subject's blood pressure and heart rate two&#xD;
           times while the study drug is being given to the subject and again after it is finished.&#xD;
           The subject will note any side effects they have during this time and after.&#xD;
&#xD;
           Subjects will then review what will happen during the MRI scan with the Investigator.&#xD;
           The MRI study will be conducted at the Magnetic Resonance Imaging Center of the&#xD;
           Department of Radiology at the Beth Israel Deaconess Medical Center.&#xD;
&#xD;
           The MRI is a method of taking pictures of the brain and of the blood flow in the brain,&#xD;
           using a large magnet and radio signals. Subjects will be asked to lie down on a platform&#xD;
           that can be slid into the magnet. An MRI imaging coil, which is made from special wires&#xD;
           that are covered in plastic, will be placed around the head. Foam pads will be placed&#xD;
           around the head to limit head movement during the scan. During the scan, subjects will&#xD;
           be asked to lie still on their back for about 45 to 60 minutes. They will hear a loud&#xD;
           knocking or hammering noise while the MRI is taking pictures, but the process itself&#xD;
           will be painless. They will be given disposable earplugs to use to help lessen the&#xD;
           noise. During the procedure, subjects will be in constant contact with the MRI&#xD;
           technician through an intercom. If at any time during the scan you feel too&#xD;
           uncomfortable to continue, no matter what the reason, the study will be immediately&#xD;
           stopped and subjects will be removed from the magnet (MRI Scanner).&#xD;
&#xD;
           Subjects will return to the Clinical Research Center after the MRI. They will take a few&#xD;
           pencil-and-paper tests for about one hour. These tests will tell the investigator about&#xD;
           memory and mood. They will also learn about your attention skills. Investigators will&#xD;
           also learn about the subjects= language skills and &quot;handedness&quot; (a tendency to favor&#xD;
           right or left hand).&#xD;
&#xD;
           As the medication (levetiracetam) may make the subject drowsy, they will not be able to&#xD;
           drive. Someone will need to accompany them to and from the hospital for the three study&#xD;
           visits.&#xD;
&#xD;
           The second and third study visits will have the same sequence of events.&#xD;
&#xD;
           SUMMARIES&#xD;
&#xD;
           Here is a summary of the Screening Visit&#xD;
&#xD;
           Screening visit / informed consent Review your medical history. Brief physical and&#xD;
           neurological exam. Paper and pencil tests. Blood drawn to check the functioning of&#xD;
           kidneys. Review and sign the informed consent form.&#xD;
&#xD;
           Here are summaries of the three Study Visits&#xD;
&#xD;
           Visit One&#xD;
&#xD;
           :&#xD;
&#xD;
           Vital signs. 2 minutes Brief physical and neurological exam. 10 minutes An intravenous&#xD;
           catheter placed in your arm. 5 minutes EEG. 60 minutes Intravenous dose of the&#xD;
           medication, levetiracetam, or placebo. 20 minutes MRI scan. 60 minutes Paper and pencil&#xD;
           tests. 60 minutes&#xD;
&#xD;
           Study Visit Two: (This visit will occur one to two (1-2 )weeks after Study Visit One)&#xD;
&#xD;
           Vital signs. 2 minutes Brief physical and neurological exam. 10 minutes Intravenous&#xD;
           catheter placed in your arm. 5 minutes EEG. 60 minutes Intravenous dose of the&#xD;
           medication, levetiracetam, or placebo. 20 minutes MRI scan. 60 minutes Paper and pencil&#xD;
           tests. 60 minutes&#xD;
&#xD;
           Study Visit Three: (This visit will occur one to two (1-2 )weeks after Study Visit Two)&#xD;
&#xD;
           Vital signs. 2 minutes Physical and neurological exam. 10 minutes Intravenous catheter&#xD;
           placed in your arm. 5 minutes EEG. 60 minutes Intravenous dose of the medication,&#xD;
           levetiracetam, or placebo. 20 minutes MRI scan. 60 minutes Paper and pencil tests. 60&#xD;
           minutes&#xD;
&#xD;
           Each visit will take a total of approximately 5 hours. This includes the time for the&#xD;
           EEG, MRI imaging and neuropsychological tests. Subjects will be allowed time to rest&#xD;
           between activities on a bed if they become tired. The CRC staff will serve lunch.&#xD;
&#xD;
        4. Monitoring/Follow-Up Procedures. Procedures performed to evaluate the effectiveness and&#xD;
           safety of the research procedures are called &quot;monitoring&quot; or &quot;follow-up&quot; procedures.&#xD;
           Subject follow-up procedure will be a phone call from the study doctor one week after&#xD;
           the third visit. They will ask if any side effects from the study or study medication&#xD;
           occurred&#xD;
&#xD;
      Timing: If subjects are enrolled into the study following the initial screening visit, each&#xD;
      of the three study visits will be separated by 2-3 week intervals. Therefore, the entire&#xD;
      study will last approximately 6-9 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 1, 2017</completion_date>
  <primary_completion_date type="Actual">July 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Evaluable fMRI Scans</measure>
    <time_frame>3 MRIs acquired at visit 2,3 and 4 between weeks 1 and 6</time_frame>
    <description>Number of participants who had evaluable fMRI scans with arterial spin labeling to measure brain perfusion blood flow changes in specific brain regions, including the hippocampus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Free and Cued Selective Reminding Test</measure>
    <time_frame>At visits 2,3,4 in weeks 1-6 (one visit per intervention, visits spaced 2 weeks apart)</time_frame>
    <description>Evaluate memory changes, the free and cued selective reminding test lists the number of items recalled from a possibility of 16, adding free recall at two time points, yielding a score on a 0-32 scale per participant. A higher score is better, representing better recall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>At visits 2,3,4 in weeks 1-6 (*one visit per intervention, visits spaced 2 weeks apart</time_frame>
    <description>Evaluate AD severity, this is a 30 point scale from 0-30, with higher scores representing better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trial Making Test Parts A &amp; B</measure>
    <time_frame>At visits 2,3,4 in weeks 1-6 (*one visit per intervention, visits spaced 2 weeks apart*</time_frame>
    <description>Evaluate visuo-spatial changes, outcome is total time to complete a task of connecting items (either numbers in trails A, or numbers alternating with letters in Trails B). A longer time indicates worse performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phonemic &amp; Category Fluency Test</measure>
    <time_frame>At visits 2,3,4 in weeks 1-6 (*one visit per intervention, visits spaced 2 weeks apart*</time_frame>
    <description>Evaluate memory changes in AD. Phonemic fluency refers to the number of items generated in one minute beginning with a specific letter. A higher score indicates more items and better performance. There is no maximum score. Category fluency refers to the number of items generated belonging to a specific category (such as animals), again, more items generated indicates better performance.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>High Dose Levetiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low Dose Levetiracetam administration via IV infusion over 20 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Levetiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Dose Levetiracetam administration via IV infusion over 20 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo administration</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline administration via IV infusion over 20 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low/High/Placebo Dose Keppra (Levetiracetam)</intervention_name>
    <description>Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)</description>
    <arm_group_label>High Dose Levetiracetam</arm_group_label>
    <arm_group_label>Low Dose Levetiracetam</arm_group_label>
    <arm_group_label>Placebo administration</arm_group_label>
    <other_name>Levetiracetam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets the NINCDS-ADRDA criteria for probable Alzheimer's disease&#xD;
&#xD;
          -  Mild AD (MMSE â‰¥ 20)&#xD;
&#xD;
          -  Age &gt;= 50 years&#xD;
&#xD;
          -  English as first language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of seizures prior to the onset of AD&#xD;
&#xD;
          -  Familial Alzheimer's Disease due to known genetic mutations&#xD;
&#xD;
          -  Current use of an antiepileptic medication&#xD;
&#xD;
          -  Current use of a medication known to lower seizure threshold (e.g. bupropion or a&#xD;
             neuroleptic)&#xD;
&#xD;
          -  Presence of parkinsonism&#xD;
&#xD;
          -  Significant cerebrovascular disease&#xD;
&#xD;
          -  Other Central Nervous System disease (e.g. stroke, severe traumatic brain injury)&#xD;
&#xD;
          -  Major depression or other psychiatric or behavioral disorders (psychosis, agitation)&#xD;
&#xD;
          -  Medical contraindication to MRI (e.g. pacemaker, intraocular or intracranial metallic&#xD;
             objects)&#xD;
&#xD;
          -  Severe claustrophobia or inability to lie flat for MRI&#xD;
&#xD;
          -  Known allergy to levetiracetam, or history of previous adverse reaction to&#xD;
             levetiracetam&#xD;
&#xD;
          -  Serum creatinine &gt;= 2&#xD;
&#xD;
          -  A score of &gt;9 on the Geriatric Depression Scale&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Press, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://tmslab.org/</url>
    <description>Berenson Allen Center Lab Website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <results_first_submitted>April 25, 2019</results_first_submitted>
  <results_first_submitted_qc>July 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2020</results_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel Press</investigator_full_name>
    <investigator_title>Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Seizures</keyword>
  <keyword>Memory</keyword>
  <keyword>Executive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT01554683/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>While 12 participants were consented, 3 withdrew prior to receiving medications. 2 were due to claustrophobia preventing MRI and one was due to inability to recall why they were doing the study (so study was discontinued prior to drug administration).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose Levetiracetam, Low Dose, Placebo</title>
          <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes followed by LEV at a dose of 2.5mg/kg over 20 minutes followed by Placebo over 20 minutes</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Levetiracetam, High Dose, Placebo</title>
          <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes followed by LEV at 7.5mg/kg over 20 minutes followed by Placebo</description>
        </group>
        <group group_id="P3">
          <title>Placebo Administration, High Dose LEV, Low Dose</title>
          <description>Saline administration via IV infusion over 20 min followed by LEV at 7.5mg/kg followed by LEV at 2.5 mg/kg</description>
        </group>
        <group group_id="P4">
          <title>High Dose LEV, Placebo, Low Dose</title>
          <description>LEV at 7.5mg/kg followed by Placebo, followed by LEV at 2.5mg/kg</description>
        </group>
        <group group_id="P5">
          <title>Low Dose LEV, Placebo, High Dose LEV</title>
          <description>Low dose LEV at 2.5mg/kg followed by placebo followed by High Dose LEV at 7.5mg/kg</description>
        </group>
        <group group_id="P6">
          <title>Placebo, Low Dose LEV, High Dose LEV</title>
          <description>Placebo, followed by low dose LEV at 2.5mg/kg followed by High dose LEV at 7.5mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Saline administration via IV infusion over 20 min, High dose LEV 7.5mg/kg, and Low dose LEV at 2.5mg/kg in random order</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Evaluable fMRI Scans</title>
        <description>Number of participants who had evaluable fMRI scans with arterial spin labeling to measure brain perfusion blood flow changes in specific brain regions, including the hippocampus</description>
        <time_frame>3 MRIs acquired at visit 2,3 and 4 between weeks 1 and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Levetiracetam</title>
            <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Levetiracetam</title>
            <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo Administration</title>
            <description>Saline administration via IV infusion over 20 min</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Evaluable fMRI Scans</title>
          <description>Number of participants who had evaluable fMRI scans with arterial spin labeling to measure brain perfusion blood flow changes in specific brain regions, including the hippocampus</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>temporal lobe perfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal lobe perfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free and Cued Selective Reminding Test</title>
        <description>Evaluate memory changes, the free and cued selective reminding test lists the number of items recalled from a possibility of 16, adding free recall at two time points, yielding a score on a 0-32 scale per participant. A higher score is better, representing better recall.</description>
        <time_frame>At visits 2,3,4 in weeks 1-6 (one visit per intervention, visits spaced 2 weeks apart)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Levetiracetam</title>
            <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Levetiracetam</title>
            <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo Administration</title>
            <description>Saline administration via IV infusion over 20 min</description>
          </group>
        </group_list>
        <measure>
          <title>Free and Cued Selective Reminding Test</title>
          <description>Evaluate memory changes, the free and cued selective reminding test lists the number of items recalled from a possibility of 16, adding free recall at two time points, yielding a score on a 0-32 scale per participant. A higher score is better, representing better recall.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="10"/>
                    <measurement group_id="O2" value="14.3" spread="5.4"/>
                    <measurement group_id="O3" value="15" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montreal Cognitive Assessment (MoCA)</title>
        <description>Evaluate AD severity, this is a 30 point scale from 0-30, with higher scores representing better performance.</description>
        <time_frame>At visits 2,3,4 in weeks 1-6 (*one visit per intervention, visits spaced 2 weeks apart</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Levetiracetam</title>
            <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Levetiracetam</title>
            <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo Administration</title>
            <description>Saline administration via IV infusion over 20 min</description>
          </group>
        </group_list>
        <measure>
          <title>Montreal Cognitive Assessment (MoCA)</title>
          <description>Evaluate AD severity, this is a 30 point scale from 0-30, with higher scores representing better performance.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="1.7"/>
                    <measurement group_id="O2" value="21.4" spread="3"/>
                    <measurement group_id="O3" value="20.4" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trial Making Test Parts A &amp; B</title>
        <description>Evaluate visuo-spatial changes, outcome is total time to complete a task of connecting items (either numbers in trails A, or numbers alternating with letters in Trails B). A longer time indicates worse performance.</description>
        <time_frame>At visits 2,3,4 in weeks 1-6 (*one visit per intervention, visits spaced 2 weeks apart*</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Levetiracetam</title>
            <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Levetiracetam</title>
            <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo Administration</title>
            <description>Saline administration via IV infusion over 20 min</description>
          </group>
        </group_list>
        <measure>
          <title>Trial Making Test Parts A &amp; B</title>
          <description>Evaluate visuo-spatial changes, outcome is total time to complete a task of connecting items (either numbers in trails A, or numbers alternating with letters in Trails B). A longer time indicates worse performance.</description>
          <units>seconds</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trails A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" spread="14.7"/>
                    <measurement group_id="O2" value="47.1" spread="25.9"/>
                    <measurement group_id="O3" value="48.9" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trails B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.3" spread="44.4"/>
                    <measurement group_id="O2" value="138.9" spread="45.3"/>
                    <measurement group_id="O3" value="153.5" spread="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phonemic &amp; Category Fluency Test</title>
        <description>Evaluate memory changes in AD. Phonemic fluency refers to the number of items generated in one minute beginning with a specific letter. A higher score indicates more items and better performance. There is no maximum score. Category fluency refers to the number of items generated belonging to a specific category (such as animals), again, more items generated indicates better performance.</description>
        <time_frame>At visits 2,3,4 in weeks 1-6 (*one visit per intervention, visits spaced 2 weeks apart*</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Levetiracetam</title>
            <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Levetiracetam</title>
            <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo Administration</title>
            <description>Saline administration via IV infusion over 20 min</description>
          </group>
        </group_list>
        <measure>
          <title>Phonemic &amp; Category Fluency Test</title>
          <description>Evaluate memory changes in AD. Phonemic fluency refers to the number of items generated in one minute beginning with a specific letter. A higher score indicates more items and better performance. There is no maximum score. Category fluency refers to the number of items generated belonging to a specific category (such as animals), again, more items generated indicates better performance.</description>
          <units>Correct Items</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phonemic fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" spread="12.5"/>
                    <measurement group_id="O2" value="34" spread="9.5"/>
                    <measurement group_id="O3" value="34.4" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Animal fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="5.5"/>
                    <measurement group_id="O2" value="13.1" spread="3.7"/>
                    <measurement group_id="O3" value="12.4" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks, from beginning of study to end of study (study consisted of 3 separate infusions, all side effects were assessed over the 6 hours after the infusions)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Dose Levetiracetam</title>
          <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Levetiracetam</title>
          <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes</description>
        </group>
        <group group_id="E3">
          <title>Placebo Administration</title>
          <description>Saline administration via IV infusion over 20 min</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Press</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-667-4074</phone>
      <email>dpress@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

